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he bilayered mammary epithelium comprises a luminal
layer of secretory cells and a basal layer of myo-
epithelial cells. Numerous data suggest the existence
 
of self-renewing, pluripotent mammary stem cells; however,
their molecular characteristics and differentiation pathways
are largely unknown. BC44 mammary epithelial cells in
 
culture, display phenotypic characteristics of basal epithe-
lium, i.e., express basal cytokeratins 5 and 14 and P-cadherin,
but no smooth muscle markers. In vivo, after injection into the
cleared mammary fat pad, these cells gave rise to bilayered,
 
hollow, alveolus-like structures comprising basal cells
expressing cytokeratin 5 and luminal cells positive for
T
 
cytokeratin 8 and secreting 
 
 
 
-casein in a polarized manner
into the lumen. The persistent stimulation of EGF receptor
signaling pathway in BC44 cells in culture resulted in the
loss of the in vivo morphogenetic potential and led to the
induction of active MMP2, thereby triggering cell scattering
and motility on laminin 5. These data (a) suggest that BC44
cells are capable of asymmetric division for self-renewal
and the generation of a differentiated progeny restricted
to the luminal lineage; (b) clarify the function of EGF in
 
the control of the BC44 cell phenotypic plasticity; and (c)
suggest a role for this phenomenon in the mammary gland
development.
 
Introduction
 
Phenotypic plasticity and the ability to acquire a motile
behavior are essential properties of epithelial cells, known to
play an important role in early development, tissue morpho-
genesis, and tumor progression. Diffusing growth factors, as
well as cell–ECM interactions, participate in the control of
 
epithelial cell phenotype. Numerous general and tissue-specific
regulatory molecules have been identified, but it remains
unclear how their signals are integrated by epithelial cells.
In mammary gland, most morphogenetic and cell dif-
ferentiation events occur postnatally. In newborn female
mouse, the mammary gland consists of a rudimentary system
of epithelial ducts embedded in fatty connective tissue. At
puberty, the mammary ducts elongate, branch, and pro-
gressively invade the entire mammary fat pad. During preg-
nancy, intensive lateral branching and alveolar development
occur, so that at parturition, the mammary fat pad is com-
pletely filled with milk-producing alveolar units.
The mammary epithelium is organized into two layers, a
luminal epithelium and a basal layer of myoepithelial cells.
The bilayer is surrounded by a basement membrane which
separates the epithelium from the connective tissue stroma.
During lactation, luminal epithelial cells differentiate into
secretory cells, whereas basal myoepithelial cells acquire a
contractile phenotype. Luminal cells are characterized by ex-
pression of the specific cytokeratin pair, keratin (K)*8 and
K18, whereas myoepithelial cells express the basal cytoker-
atins, K5 and K14, along with P-cadherin and smooth
muscle contractile proteins (Sonnenberg et al., 1986; Tay-
lor-Papadimitriou and Lane, 1987; Daniel et al., 1995;
Deugnier et al., 1995).
Data obtained from the serial transplantation of mammary
epithelial fragments strongly suggest that pubescent and
adult mammary epithelium, like other epithelial tissues, con-
tains self-renewing, pluripotent stem cells capable of giving
rise to lineage-restricted progenitors for luminal and myoepi-
thelial cells (Daniel et al., 1968; Smith and Medina, 1988;
Kordon and Smith, 1998; Slack, 2000; Watt and Hogan,
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2000; Smith and Chepko, 2001). The phenotype and loca-
tion of these cells in mammary epithelium remain uncer-
tain. Recent in vitro experiments based on cell separation
techniques have suggested that bipotent mammary precur-
sor cells belonged to the luminal compartment (Pechoux et
al., 1999; Smalley et al., 1999). Other studies provided ev-
idence that precursor cells in the human mammary gland
display basal characteristics (Stingl et al., 2001; Böcker et
al., 2002). In addition, the so-called cap cells, located at
the edge of terminal end buds (bulbous structures found at
the apex of elongating ducts in the pubertal mouse mam-
mary gland) have been proposed to possess important mor-
phogenetic properties and to serve as progenitors for both
luminal and myoepithelial cells (Dulbecco et al., 1983;
Williams and Daniel, 1983). Finally, extensive ultrastruc-
tural studies revealed undifferentiated “pale” or “light”
cells resting on the basement membrane or the suprabasal
surface of myoepithelial cells. These cells are rare, but they
are present at all stages of mammary development and are
distributed throughout the mammary tree (Smith and Me-
dina, 1988; Smith and Chepko, 2001).
We recently established and characterized mouse mam-
mary epithelial cell lines (BC20 and BC44) that express
high levels of the basal cell markers, K5/K14 and P-cad-
herin (Deugnier et al., 1999). These basal mammary epi-
thelial cells appear to have a plastic phenotype. Cultured
in the absence of EGF, basal cells displayed well-devel-
oped cell–ECM contacts and were deficient in cell–cell
junctions. Culture in the presence of EGF for 8–10 d re-
sulted in a decrease in focal contact number and the es-
tablishment of cell–cell junctions. These morphological
changes were accompanied by the down-regulation of
basal marker protein and mRNA levels, indicating that, in
culture, EGF acts as a negative regulator of the basal cell
phenotype. The effects of EGF treatment were reversible
because, after the removal of EGF from the culture me-
dium, the cells progressively returned to the basal pheno-
type, as shown by changes in cell–cell and cell–ECM ad-
hesion and the up-regulation of basal markers (Deugnier
et al., 1999). Neither EGF-treated, nor untreated cells ex-
pressed detectable amounts of the keratins characteristic
of the luminal layer, K8 and K18.
Figure 1. In vivo developmental 
potential of BC44 cells. Untreated and 
EGF-treated BC44 cells were transplanted 
into the cleared mammary fat pad of 
prepubertal mice, and the outgrowths 
obtained were analyzed 5 wk after 
transplantation. (A) Haematoxylin-eosin–
stained sections of the outgrowths derived 
from untreated (a) and EGF-treated (b) 
BC44 cells. Untreated BC44 cells form 
lumen-containing ramified structures, 
whereas EGF-treated cells remain scat-
tered throughout the stroma. Bar, 40  m. 
(B) Detection of transplanted cells by 
immunofluorescence labeling. Serial 
sections of the outgrowths derived from 
untreated and EGF-treated BC44 cells 
were stained with anti-pan-cytokeratin 
(a and b), anti-K5 (c and d), and anti-LN5 
(e and f, red) antibodies. DAPI-stained 
nuclei are shown in blue (c–f). The epi-
thelial structures formed by untreated 
BC44 cells (a, c, and e) comprise basally 
located K5-positive cells (c) resting on a 
LN5-containing basement membrane (e). 
EGF-treated cells (b, d, and f) remain dis-
organized, and LN5 deposition is patchy. 
Bar, 25  m. (C) Double immunofluores-
cence staining of epithelial bilayer struc-
tures derived from untreated BC44 cells 
with anti–pan-cytokeratin (a) and anti-
K18 (b) antibodies; the merged image is 
shown in (c). Note that untreated BC44 
cells established a bilayered epithelium 
and differentiated into K18-positive 
luminal cells. Bar, 15  m. (D) Sections 
of the outgrowths formed by untreated 
BC44 cells in the mammary fat pad of 
14-d-pregnant mouse were stained with 
anti– -casein antibody.  -Casein (red) is 
detected in the cytoplasm of the luminal 
cells (a) and in the lumen of the bilayered 
structures (b). DAPI-stained nuclei are 
shown in blue. Bar, 15  m. 
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Considering their remarkable phenotypic plasticity, we
decided to study the developmental potential of BC44 cells
in vivo. We have found that BC44 cells cultured in the ab-
sence of EGF after injection into the cleared mouse mam-
mary fat pad, were able to differentiate into luminal, secre-
tory cells and establish a bilayer with luminal and basal cells
expressing specific keratins. Long-term treatment with EGF
in culture resulted in the loss of the in vivo morphogenetic
potential and led to the induction of active MMP2, thereby
triggering cell scattering and motility on laminin (LN)5.
These results reveal that BC44 cells possess luminal lineage-
restricted progenitor properties and suggest a role for EGF
in the control of the mammary progenitor cell phenotype.
 
Results
 
Basal mammary epithelial cells possess an important 
developmental potential
 
BC44 cells, either untreated or treated with EGF, were in-
jected into the cleared mammary fat pads of 3-wk-old synge-
neic female mice. In both cases, whole-mount staining of
the fat pads performed 4 wk after injection revealed solid
outgrowths of up to 5 mm in size (unpublished data). His-
tological analysis revealed that untreated basal cells formed
lumen-containing, ramified epithelial structures, whereas EGF-
treated cells were predominantly scattered throughout the
stroma, with only rare cyst-like structures detected (Fig. 1 A).
The epithelial structures derived from untreated basal cells
formed a properly polarized bilayer, with a luminal K18-pos-
itive and a basal K5-positive cell layer (Fig. 1, B and C).
These bilayer structures were surrounded by a basement
membrane that contained LN5. In the outgrowths derived
from EGF-treated basal cells, epithelial cells, as detected with
a pan-keratin antibody, were mostly scattered throughout the
stroma, and LN5 deposition was diffuse (Fig. 1 B). These
outgrowths contained some epithelial cells that expressed K5
(Fig. 1 B), but no K18-positive cells (unpublished data). We
analyzed the ability of untreated BC44 cells to acquire a fully
differentiated phenotype, by mating the host mice 6 wk after
injection, and dissecting the mammary fat pads containing
the outgrowths on the 14th day of pregnancy. The bilayer
structures formed by untreated BC44 cells in the pregnant
mice contained luminal cells that synthesized 
 
 
 
-casein and
secreted it into the lumen (Fig. 1 D). 
 
 
 
-Smooth muscle ac-
tin, a marker of myoepithelial cells, was not expressed in the
epithelial bilayer structures established by the transplanted
cells in virgin and pregnant animals (unpublished data).
Therefore, we concluded that basal BC44 cells cultured in
the absence of EGF retain considerable developmental poten-
tial: they can differentiate into luminal, secretory cells, and
establish a bilayer with luminal and basal cells expressing spe-
cific keratins. In contrast, EGF-treated basal cells displayed
low morphogenetic competence, and remained scattered
throughout the stroma, displaying an invasive phenotype.
 
Basal mammary epithelial cells grown in the presence 
of EGF acquire the ability to migrate on LN5
 
Cells engaged in morphogenetic processes interact with the
ECM. Depending on the developmental context, the ECM
may be involved in cell anchorage or may provide a substrate
for migration. Therefore, we compared the adhesive charac-
teristics and motility of basal cells grown in the presence and
absence of EGF. Cell attachment assays revealed that both
untreated and EGF-treated BC44 cells adhered strongly to
LN5 and FN. They adhered less strongly to LN1, and not at
all to collagens I and IV (Fig. 2 A). EGF treatment slightly
reduced adhesion to FN but had no effect on cell attach-
ment to LN1 and LN5.
Figure 2. Effects of EGF treatment on BC44 cell adhesion to ECM 
proteins and the integrin repertoire. (A) Cell adhesion assays. 
Untreated (white bars) and EGF-treated BC44 cells (gray bars) 
adhered well to LN5, FN, and LN1 and did not attach to CI and CIV. 
EGF treatment resulted in a small decrease in adhesion to FN. Each 
bar represents the mean of three independent measurements   SD. 
(B) Flow cytometry analysis of integrin levels in untreated (normal 
lines) and EGF-treated (bold lines) BC44 cells. Untreated and EGF-
treated BC44 cells did not express  1 or  2 and displayed similar 
amounts of  3,  v,  6,  1, and  4 integrin chains. Expression of  5 
chain and of the  1 chain epitope recognized by the 9EG7 antibody 
( 1*) were reduced upon EGF treatment. Dotted lines show negative 
controls in which the primary antibody was omitted. 
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Flow cytometry analysis showed that long-term EGF
treatment did not significantly affect the basal cell integrin
repertoire. Untreated and EGF-treated BC44 cells produced
large amounts of 
 
 
 
1, 
 
 
 
3, 
 
 
 
6, and 
 
 
 
4 integrin chains and
small to moderate amounts of 
 
 
 
5 and 
 
 
 
 
 
v
 
, whereas neither
the 
 
 
 
1 nor the 
 
 
 
2 chain was detected (Fig. 2 B). Interest-
ingly, levels of the 
 
 
 
5 integrin chain and of a 
 
 
 
1 integrin
chain epitope recognized by the 9EG7 monoclonal antibody
were higher in untreated BC44 cells. The 9EG7 epitope was
reported to be induced upon ligand occupancy or Mn
 
2
 
 
 
stimulation of the FN receptor, 
 
 
 
5
 
 
 
1 (Bazzoni et al., 1998).
Thus, the higher levels of both the 
 
 
 
5 chain and the 9EG7
epitope in untreated BC44 cells may account for the stron-
ger adhesion of these cells to FN (Fig. 2).
We evaluated the ability of basal cells to migrate in re-
sponse to ECM stimulation by monitoring the dispersion of
cellular aggregates deposited on surfaces coated with individ-
ual ECM proteins. After 24 h of shaking in culture medium,
isolated EGF-treated cells assembled into compact multicel-
lular aggregates, whereas untreated cells formed loose cell
clusters (Fig. 3 A). These observations are consistent with our
previous work showing that BC44 cells were able to estab-
lish firm cell–cell junctions only after treatment with EGF
(Deugnier et al., 1999). Cellular aggregates formed by EGF-
treated BC44 cells and deposited on ECM protein coated
surfaces, after 24 h of contact with ECM, were well spread on
FN and LN5, and poorly spread on CIV and LN1. Notably,
LN5 was the only ECM protein able to induce the dispersion
of cellular aggregates, as intercellular interactions were main-
tained on FN, preventing cells from scattering (Fig. 3 B).
Furthermore, if EGF-treated BC44 cells in single-cell suspen-
sions were plated on FN, they appeared to be well spread and
displayed numerous focal adhesions typical of stationary cells
(Fig. 4). In contrast, on LN5, EGF-treated BC44 cells were
polarized, with extended lamellipodia and filopodia typical of
motile cells, and actin stress fibers and focal adhesions ap-
peared to be much less prominent than on FN. Untreated
cells were well spread on FN and LN5, and displayed abun-
dant, well-formed stress fibers and focal adhesions (Fig. 4).
We assessed the migratory behavior of basal cells on ECM
proteins directly by monitoring cell migration for 14 h with a
time-lapse video recorder. Representative tracks of untreated
and EGF-treated BC44 cells plated on LN5 and histograms
of cell migration rates are shown in Fig 5. The individual cell
tracks clearly indicate marked differences in the migratory
behavior of the cells tested. On LN5, the untreated BC44
cells remained stationary or migrated over very short dis-
tances (Fig. 5 A), whereas the majority of EGF-treated cells
were highly motile, displaying both directional and random
movements. Quantitative analysis of the migration assay re-
sults indicated that 75% of EGF-treated BC44 cells, and
only 14% of untreated cells, migrated on LN5 at speeds 
 
 
 
20
 
 
 
m/h (Fig. 5 B). The rate of 20 
 
 
 
m/h was used as a thresh-
old, above which cells were considered to be essentially mo-
tile. Additional experiments demonstrated that BC44 cells,
regardless of EGF treatment, were poorly motile on LN1 and
stationary on FN (Fig. 5 B). The movement of basal cells on
LN5 was inhibited by function-blocking anti–
 
 
 
1-integrin
and anti-LN5 antibodies (unpublished data). Thus, basal
cells subjected to long-term EGF treatment switched from a
stationary to a motile phenotype, and LN5 played a specific
role in promoting the migration of these cells.
Figure 3. Effects of EGF treatment on the formation and dispersion 
of BC44 cell aggregates. (A) After 48 h of shaking, untreated BC44 
cells (left) formed loose cell clusters, whereas EGF-treated cells 
(right) assembled into compact, multicellular aggregates. Bar, 50 
 m. (B) After 24 h, the aggregates formed by EGF-treated BC44 cells 
were well spread on FN and LN5, and poorly spread on CIV and 
LN1. Notably, LN5 induced the dispersion of cellular aggregates, 
whereas intercellular interactions were maintained on FN, preventing 
cells from scattering. Bar, 100  m.
Figure 4. Cytoskeleton organization in BC44 cells plated on FN 
and LN5. Double immunofluorescence staining (actin, green; vinculin, 
red) of untreated (A and B) and EGF-treated BC44 cells (C and D) 
plated on FN (A and C) or LN5 (B and D). Untreated BC44 cells 
were well spread and exhibited prominent actin stress fibers and 
focal adhesions on FN, as well as on LN5. EGF-treated BC44 cells 
were polarized, with the extended lamellipodia and filopodia char-
acteristic of motile cells. EGF treatment greatly reduced the numbers 
of actin stress fibers and focal adhesions on LN5. Bar, 20  m. 
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To study the role of EGFR signaling in LN5-dependent
basal cell migration, we first compared the EGFR levels ex-
pressed on the surface of basal cells grown in the presence or
absence of EGF. Flow cytometry analysis revealed that EGF-
treated and untreated cells presented similar levels of EGFR
(Fig. 6 A). The aggregate dispersion and migration assays de-
scribed above (Figs. 3 and 5) were all performed in the ab-
sence of EGF. The addition of EGF to the incubation me-
dium in cell migration assays had no major effect on the
migratory behavior of BC44 cells on LN5 (Fig. 6 B). These
results suggest that ligand-dependent EGFR activation was
not involved in the LN5-dependent motility of BC44 cells.
 
EGF treatment induces the secretion of active MMP2, 
which is required for the migration of basal mammary 
epithelial cells on LN5
 
In a variety of epithelial cell lines, migration on LN5 has
been shown to depend on LN5 
 
 
 
2 chain cleavage by the ge-
latinase MMP2 (Giannelli et al., 1997; Koshikawa et al.,
2000). We used gelatin zymography to compare MMP2 and
MMP9 activities in conditioned media obtained from un-
treated and EGF-treated BC44 cells (Fig. 7 A). Zymograms
clearly indicated that unlike untreated cells, EGF-treated
basal cells, produced an important gelatinolytic activity cor-
responding to the active 62-kD and the latent 72-kD forms
of MMP2. Treated and untreated basal cells produced mod-
erate amounts of a gelatinolytic activity that could be attrib-
uted to the latent 92-kD form of MMP9, and, as seen by
Figure 5. Effects of EGF treatment on the migratory behavior of 
BC44 cells on ECM proteins. (A) Representative tracks of untreated 
(a) and EGF-treated (b) BC44 cells plated on LN5. Cell migration 
was recorded at 20-min intervals over a period of 14 h. Most of the 
untreated BC44 cells did not move on LN5 or migrated over only 
short distances. In contrast, most EGF-treated cells migrated over 
long distances at speeds of over 20  m/h. (B) Histograms of cell 
migration rates obtained for untreated (a) and EGF-treated (b) BC44 
cells plated on LN5, LN1, or FN. None of the ECM proteins induced 
motility in untreated BC44 cells, whereas LN5 delivered migratory 
stimuli to EGF-treated cells. The mean speed of migration of EGF-
treated cells on LN5 was 48   14  m/h. At least two replicates 
were performed for each experiment.
Figure 6. Expression of EGFR and role of EGFR signaling in BC44 
cell migration on LN5. (A) Flow cytometry analysis of EGFR expression 
in untreated and EGF-treated BC44 cells (bold lines). Basal cells 
expressed significant levels of EGFR, regardless of EGF treatment. 
The dotted line corresponds to negative control performed with 
an isotype-matched irrelevant antibody. (B) Effects of EGF on the 
migratory behavior of untreated (a) and EGF-treated (b) BC44 cells. 
EGF neither triggered the migration of untreated basal cells anchored 
to LN5, nor significantly stimulated the constitutive motility of EGF-
treated cells. In each experiment, 25 cell tracks were analyzed. 
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plasminogen zymography, similar amounts of urokinase
plasminogen activator (u-PA), revealed as a proteolytic band
of 33 kD (Fig. 7 A).
In agreement with the results of gelatin zymography, com-
parative analysis of the conditioned medium from EGF-
treated and untreated cells by Western blotting using anti-
bodies specific for pro-MMP2 has revealed that treated cells
secreted a higher amount of pro-MMP2 than untreated cells
(Fig. 7 B). However, we did not observe any difference in
MMP2 mRNA levels in treated and untreated cells using
semiquantitative and real-time RT-PCR assays (Fig. 7 C;
unpublished data). Similarly, the expression of MT1-MMP,
a transmembrane matrix metalloproteinase implicated in the
activation of MMP2 and in the cleavage of the LN5 
 
 
 
2
chain (Strongin et al., 1995; Koshikawa et al., 2000) was not
affected by EGF treatment (Fig. 7 C).
The high levels of MMP2 production in EGF-treated
basal cells were correlated with migratory behavior, suggest-
ing that LN5-induced basal cell motility was an MMP2-
dependent process. Consistent with this, we found that the
constitutive migration of EGF-treated BC44 cells on LN5
was inhibited by marimastat, a synthetic inhibitor of MMPs,
and significantly reduced in the presence of TIMP2, the nat-
ural inhibitor of MMP2 (Fig. 7 D). Morerover, the incuba-
tion of LN5 with MMP2 before the migration assay induced
motility in untreated BC44 cells (Fig. 7 E).
These data demonstrate that, in basal cells, EGF treat-
ment specifically induced the secretion of active MMP2, and
that the extracellular cleavage of LN5 by active MMP2 was
required for basal cell migration. The observed up regulation
of MMP2 expression occurred at posttranscriptional level.
 
EGF treatment concomitantly induces BC44 cell motility, 
MMP2 production, and loss of the in vivo 
morphogenetic potential
 
To study whether the in vitro phenotypic changes of BC44
cells resulting from EGF treatment, i.e., acquisition of a mo-
tile phenotype and MMP2 production, can be correlated
with a loss of the in vivo morphogenetic potential, we have
analyzed the time course of the EGF-induced phenotypic
transition. Cells cultured in the presence of EGF for differ-
ent time periods were tested for their ability to migrate on
LN5, produce MMP2 and form organized bilayered struc-
tures in vivo. We have found that the number of motile
BC44 cells progressively increased in accordance with the
length of EGF treatment (Fig. 8 A). In parallel, BC44 cells
gradually increased their production of MMP2, as revealed
by gelatin zymography performed with the conditioned me-
dia (Fig. 8 B). Overall, although after 2–4 days of culture in
the presence of EGF, BC44 cells were able to migrate and
produced significant amount of MMP2, their transition was
accomplished only by 9 d of culture. Consistently, the mor-
phogenetic potential of BC44 cells progressively decreased
with EGF treatment, so that organized structures were ob-
served only in three out of six outgrowths after 2–4 d of
treatment, and in three out of nine after 9 d. These results
Figure 7. Induction of active MMP2 by 
EGF, and MMP requirement for BC44 
cell migration on LN5. (A) Analysis of 
the proteolytic activities found in the 
conditioned media of untreated ( ) and 
EGF-treated ( ) BC44 cells. (Top) Gelatin 
zymogram. EGF-treated cells produce 
large amounts of 62-kD active and 
72-kD latent form of MMP2. The gelatin-
olytic activities above 83 kD produced 
by untreated and treated cells corre-
spond to the latent 92 kD form of MMP9 
(pro-MMP9). (Bottom) Plasminogen 
zymogram. Regardless of EGF treatment, 
BC44 cells produce urokinase, revealed 
as a proteolytic band at 33 kD (u-PA). 
Negative images are presented with the 
proteolytic bands shown in black. (B) 
Relative expression levels of pro-MMP2 
in the conditioned media of untreated 
( ) and EGF-treated ( ) BC44 cells ana-
lyzed by Western blotting. EGF-treated 
cells produce higher levels of pro-MMP2 
than untreated cells. (C) RT-PCR analysis 
of MMP2 and MT1-MMP expression in 
untreated ( ) and EGF-treated ( ) BC44 
cells. Treated and untreated BC44 cells 
produce similar amounts of MMP2 and 
MT1-MMP transcripts. The translation 
factor, EF1 , was used as control. (D) 
Inhibitory effects of Marimastat, a syn-
thetic inhibitor of MMPs, and TIMP2, the natural inhibitor of MMP2, on the LN5-dependent migration of EGF-treated BC44 cells. (E) Migration 
of untreated BC44 cells plated on MMP2-cleaved LN5. Petri dishes coated with LN5 were incubated with active MMP2 or with inactive 
pro-MMP2 for 3 h before plating the cells. Cleaved LN5 promoted the migration of untreated BC44 cells which were otherwise stationary. 
(D and E) 25 cell tracks were analyzed in each experiment. 
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suggest that the loss of the in vivo morphogenetic potential
of BC44 cells upon long-term treatment with EGF may be
directly related to the acquisition of a MMP-dependent mo-
tile behavior.
 
Discussion
 
Our knowledge concerning the location and molecular
characteristics of mammary pluripotent stem cells and the
segregation of the two major epithelial cell lineages, basal
and luminal, is still very limited. We have isolated a mam-
mary epithelial cell line, BC44, which displays remarkable
phenotypic plasticity and morphogenetic properties (Deug-
nier et al., 1999; this study, Fig. 9). BC44 cells routinely
grown in the absence of EGF express exclusively basal
markers, K5/K14 and P-cadherin, and no luminal keratins
K8/K18. In vivo, when injected into the cleared mammary
fat pad of young prepubertal mice, these cells gave out-
growths containing ramified, bilayer structures, consisting
of K18-positive luminal cells and basally located K5/K14-
positive cells, similar to the small ducts and alveoli of the
mammary gland. Furthermore, in pregnant recipient mice,
the luminal cells of the ductal and alveolus-like structures
in the outgrowths synthesized 
 
 
 
-casein and secreted it into
the lumen. Notably, the basal cells of the observed bilayer
structures expressing K5/K14 did not express the essential
smooth muscle marker, 
 
 
 
-smooth muscle actin, and were
therefore unable to differentiate into myoepithelial cells.
Taken together, these results suggest that BC44 cells are
capable of asymmetric division, for self-renewal and the
generation of a differentiated progeny restricted to the lu-
minal lineage.
BC44 cells are clonal derivatives of the HC11 mouse mam-
mary cell line, which is in turn derived from COMMA-D, iso-
lated from the normal mammary gland of a mouse in midpreg-
nancy (Danielson et al., 1984; Ball et al., 1988). The parental
cell line, COMMA-D, in vivo, injected into the mammary fat
pad, displayed morphogenetic properties; therefore, it was sug-
gested that this cell line contained a population of mammary
epithelial stem cells (Medina et al., 1986). Unlike the highly
homogeneous BC44 cell clone expressing exclusively basal ker-
atins, COMMA-D is highly heterogeneous, and consists of
cells testing positive for basal and luminal keratins and display-
ing different morphologies. Further molecular characterization
of COMMA-D cells is required to identify the individual cell
lineages involved in morphogenesis. To our knowledge, none
of the other mammary epithelial cell lines shown to possess
morphogenetic properties (i.e., to form branching structures in
collagen gel and Matrigel) has been reported to establish a bi-
layer similar to that found in mammary gland (Berdichevsky et
al., 1994; Soriano et al., 1995; Oft et al., 1996; Stahl et al.,
1997; Hirai et al., 1998; Niemann et al., 1998).
BC44 cells grown in the presence of EGF lost their mor-
phogenetic potential and ability to differentiate into luminal
secretory cells, and remained scattered, after their injection
Figure 8. Time course of the induction of BC44 cell ability to 
migrate on LN5 and produce MMP2 after EGF treatment. (A) LN5-
induced migration of BC44 cells after EGF treatment for 2, 4, 9, and 
 9 d. (B) Gelatin zymogram showing MMP2 activities found in the 
conditioned media of BC44 cells cultured in the presence of EGF for 
2, 4, 9, and  9 d. (A and B), control, untreated BC44 cells are 
referred to as 0 d. Note that the number of motile BC44 cells and 
the production of MMP2 progressively increased in accordance 
with the length of EGF treatment.
Figure 9. Phenotypic plasticity and morphogenetic potential of 
the basal mammary epithelial BC44 cells. Cultured in the absence 
of EGF, BC44 cells expressed high levels of basal layer-specific 
proteins, such as K14, and displayed strong cell-ECM interactions 
and a deficiency in cell–cell junctions. After transplantation into the 
cleared mammary fat pad, they formed lumen-containing bilayer 
structures comprising basally located cells expressing K14, and 
luminal cells expressing K18 and secreting  -casein. Upon EGF 
treatment, K14 expression was down-regulated, basal cells established 
cell–cell junctions and acquired the ability to secrete active MMP-2 
and to migrate on LN5. These EGF-treated cells had a very weak 
morphogenetic potential. 
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into the cleared mammary fat pad. EGF is a ligand of
EGFR, a member of the ErbB/type 1 family of receptor ty-
rosine kinases. In the mouse mammary gland, EGFR is ex-
pressed in the basal myoepithelial cell layer and in cap cells
at a higher rate than in the luminal cells, and is also present
in the stroma surrounding growing epithelial ducts (DiAu-
gustine et al., 1997; Coleman et al., 1988). Direct analysis of
mammary glands from EGFR-negative mice has not been
possible due to embryonic or perinatal lethality (for review
see Olayioye et al., 2000). However, several studies carried
out in vivo have revealed that signaling via both the stromal
and the epithelial EGFR is important for mammary duct de-
velopment (Xie et al., 1997; Luetteke et al., 1999; Wiesen et
al., 1999). In particular, the targeted expression of a domi-
nant-negative form of EGFR in the luminal epithelium and
the extinction of amphiregulin, an EGFR ligand, result in
defective duct growth (Xie et al., 1997; Luetteke et al.,
1999). Consistently, if delivered in situ, via slow-release
plastic implants, EGF was shown to reinitiate duct growth
in the resting adult mammary gland, by reestablishing grow-
ing buds with a basal cap cell layer (Coleman et al., 1988).
Overall, the biological responses of mammary epithelium to
EGFR ligands in vivo are not yet well understood.
We studied the effects of EGF treatment on the basal cell
phenotype by comparing the adhesive properties and migra-
tory behavior of BC44 cells grown in the presence and ab-
sence of EGF. Persistent stimulation of the EGFR signaling
pathway (cells cultured in the presence of 10 ng/ml EGF)
did not significantly change the integrin repertoire of BC44
cells or the ability of these cells to attach to ECM proteins.
However, EGF treatment resulted in acquisition of the abil-
ity to secrete large amounts of pro- and active MMP2 and
to migrate on LN5. Untreated cells produced only small
amounts of this MMP and remained stationary on LN5.
Previous experiments performed in vitro and in vivo have
demonstrated that MMPs, in particular MMP2, MMP9,
and MT1-MMP, are downstream targets of the EGFR sig-
naling pathway (Kondapaka et al., 1997; Miettinen et al.,
1999, Kheradmand et al., 2002). MMPs are ECM-degrad-
ing proteases responsible for the matrix remodelling required
for cell migration during normal mammary development
and tumor progression (McCawley and Matrisian, 2001).
They have been reported to induce the migration of vari-
ous epithelial cells on LN5 (Giannelli et al., 1997; Ko-
shikawa et al., 2000). According to the current model,
MMP2 and the transmembrane MMP, MT1-MMP, cleave
the 
 
 
 
2 chain of LN5, thereby modifying the adhesive func-
tions of LN5 and disturbing molecular interactions with
other basement membrane components (Koshikawa et al.,
2000; Gagnoux-Palacios et al., 2001). BC44 cell migration
on LN5 appeared to be an MMP-dependent process, as it
was blocked by Marimastat, a synthetic inhibitor of MMPs,
and by TIMP2, a natural MMP inhibitor. The observed in-
duction of pro- and active MMP2 expression upon EGF
treatment led us to suggest that migration of BC44 cells on
LN5 is mediated by this metalloproteinase; however, as re-
vealed by RT-PCR, BC44 cells express also MT1-MMP.
Therefore, it can not be excluded that both MMP2 and
MT1-MMP participate in BC44 cell migration on LN5. In
addition, MT1-MMP may be involved in the MMP2 activa-
tion (Strongin et al., 1995; Kheradmand et al., 2002). Nota-
bly, LN5 preparation used in this study consisted of mole-
cules containing the putative MMP2 and MT1-MMP
cleavage site (Giannelli et al., 1997; Koshikawa et al., 2000).
However, the detailed analysis of the 
 
 
 
2-chain cleavage by
EGF-treated basal cells remains to be performed.
Importantly, untreated basal cells, which are normally sta-
tionary, acquired the ability to migrate on LN5 if this mole-
cule was cleaved by activated MMP2 before the motility as-
say. Thus, both autocrine and paracrine processing of LN5
may induce basal cell migration. Finally, LN5, a prominent
component of the basement membrane surrounding the
mammary epithelial bilayer, appears to possess a unique dual
potential, as, on the one hand, it serves for anchorage, and,
on the other hand, promotes motility of various types of epi-
thelial cells (Miyazaki et al., 1993; Zhang and Kramer, 1996;
Giannelli et al., 1997; Goldfinger et al., 1998; Koshikawa et
al., 2000). Accordingly, we found that untreated BC44 were
stationary on LN5, whereas after EGF treatment, equipped
with active MMP2, they required LN5 for the disruption of
cell–cell junctions and for motility. It should be considered
that basal cells produce and secrete their own LN5 that may
participate in the control of their behavior. EGF has been
shown to increase LN5 production in certain human carci-
noma cell lines (Mizushima et al., 1996). Our preliminary re-
sults suggest that EGF treatment does not significantly alter
overall LN5 production by basal cells, but rather results in
changes in 
 
 
 
2-chain processing (unpublished data).
It remains unknown whether pluripotent progenitor
cells in the mammary gland possess a capacity to migrate.
In this context, it is worth mentioning that pluripotent or
stem cells of the skin residing in the hair follicle bulge re-
gion have been shown to be able to exit from this niche
and to migrate along the hair follicle to populate various
compartments of the skin (Taylor et al., 2000; Oshima et
al., 2001). Several lines of evidence suggest that the basal
cell plasticity described in this paper is relevant to the dif-
ferentiation and morphogenetic events that take place
during mammary gland development. MMPs have been
reported to play an important role in the branching mor-
phogenesis of primary mammary organoids (Simian et al.,
2001). MMP2 has been detected at all stages of mouse
mammary development and localized to stromal compo-
nents and the basal epithelial cell layer (for review see Ru-
dolph-Owen and Matrisian, 1998). Furthermore, the LN5
 
 
 
2 chain fragment corresponding in size to that generated
by MMP2-cleavage has been shown to be present in the
developing mammary gland (Giannelli et al., 1999). Thus,
LN5 cleavage by MMP2, and the resulting induction of
basal cell migration may occur during mammary gland de-
velopment, particularly in the growing terminal buds, spe-
cific structures that provide a site for a variety of develop-
mental phenomena, including morphogenesis and stromal
invasion. The undifferentiated cap cells of the ductal end
buds that have been reported to possess a migratory poten-
tial (Williams and Daniel, 1983) have a phenotype remark-
ably similar to that of EGF-treated BC44 cells. Indeed, the
cap cells express a very low amount, if any, of basal keratins
K5/K14, do not express luminal keratins and are negative
for smooth muscle markers (Sapino et al., 1993). 
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It is conceivable that the embryonic mammary buds al-
ready contain the entire progenitor cell pool that serves
later to generate the ductal and the alveolar structures in the
adult gland. Notably, the basal layer of the mammary buds
from 16- to 17-d-old mouse and rat embryos, is comprised
by cells possessing a phenotype characteristic of the un-
treated BC44 progenitor cells, i.e., non-myoepithelial, but
K14-positive (Deugnier et al., 1995; unpublished data). A
recent study by Jonkers et al. (2001) has clearly demon-
strated that in the mammary gland, K14-positive cells can
give rise to both basal and luminal cells, thus proving the
existence of the mammary precursor cells expressing basal
characteristics. Moreover, a population of putative progeni-
tor cells expressing K5/K14, but negative for K8/K18 and
 
 
 
-smooth muscle actin, was recently described in adult hu-
man breast tissue (Böcker et al., 2002).
In conclusion, we report here that BC44 cells recapitulate
a large part of the mammary epithelial cell developmental
program and, in vivo, after their transplantation into mam-
mary connective tissue, these cells form branching, lumen-
containing, epithelial bilayer structures including secretory
cells. Long-term treatment with EGF in vitro leads to a phe-
notypic transition: induction of active MMP2, acquisition
of motility, and loss of morphogenetic potential. Under
these conditions, LN5 serves as a scattering agent and a sub-
strate for motility. These results strongly suggest that BC44
cells possess properties of mammary progenitors with a dif-
ferentiation potential restricted to the luminal lineage, and
provide evidence that EGF, and interactions with LN5 are
important regulators of their phenotype.
 
Materials and methods
 
Cell culture
 
Establishment of the basal mouse mammary epithelial cell line BC44 was
described in a previous article (Deugnier et al., 1999). Basal cells were
routinely grown in RPMI 1640 (GIBCO BRL; Life Technologies) supple-
mented with 10% FCS (Seromed; Biochrom KG), 2 mM 
 
L
 
-glutamine
(GIBCO BRL), 5 
 
 
 
g/ml bovine insulin (Sigma-Aldrich), and penicillin-strep-
tomycin (GIBCO BRL). When mentioned, murine EGF (Sigma-Aldrich) was
added to the culture medium at a concentration of 10 ng/ml.
 
Cell attachment assays
 
For attachment assays, 96-well tissue culture plates were coated by incu-
bation overnight at 4
 
 
 
C with 4 
 
 
 
g/ml LN5, or with other ECM proteins, all
used at a concentration of 20 
 
 
 
g/ml. Nonspecific binding sites were
blocked by incubation for 1 h at 37
 
 
 
C with 1 mg/ml heat-inactivated BSA
in PBS. 100,000 cells in 100 
 
 
 
l of RPMI were added to each well and al-
lowed to adhere for 30 min at 37
 
 
 
C. After gentle washing, attached cells
were fixed with 1% glutaraldehyde for 10 min at room temperature,
washed with PBS, stained with 0.1% crystal violet (Sigma-Aldrich) for 20
min, washed with water, and extracted with 0.2% Triton X100 for 10 min.
Absorbance was read at 595 nm.
Cell motility and aggregate dispersion assays
Freshly trypsinized 10
5 cells were resuspended in culture medium and
plated on 35-mm bacterial Petri dishes coated with ECM proteins as de-
scribed above. The plates were incubated for 2 h at 37 C, unattached cells
were gently removed and fresh EGF-free culture medium containing, when
specified, function-blocking antibodies, EGF or drugs, was added. Cell mi-
gration was monitored at 37 C for 14 h in a humidified atmosphere con-
taining 5% CO2 using time-lapse video equipment. In each experiment,
we analyzed the movements of 25–50 cells. As indicated, in some cases
the LN5-coated Petri dishes were treated with 100 nM active recombinant
human MMP2 (Calbiochem) in Tris buffer supplemented with 0.02% Brij
35, or with 100 nM purified human pro-MMP2 (Chemicon International,
Inc.) in PBS for 3–4 h at 37 C.
To prepare cellular aggregates for dispersion assays, 5   10
6 trypsinized
cells in culture medium were inoculated into a sterile silicon-treated screw-
cap Erlenmeyer flask, allowed to equilibrate in a CO2 incubator and trans-
ferred to a rotary shaker (75 rpm) for 48 h. Cellular aggregates were col-
lected by centrifugation, rinsed with culture medium, and plated on Petri
dishes previously coated with FN, CIV, LN1, or LN5. After incubation for
24 h, the cells were photographed with a Nikon phase-contrast microscope.
Western blotting
Media conditioned by BC44 cells were prepared as for zymography, and
specimens (30  g of total protein each) were loaded on a 10% SDS-PAGE.
After electrophoresis, proteins were transferred to PVDF membranes ac-
cording to the manufacturer’s instructions (Millipore). Membranes were in-
cubated in 5% milk in PBS-0.1% Tween 20 for 1 h at room temperature, in
order to prevent nonspecific protein binding, and treated overnight at 4 C
with 1  g/ml of a monoclonal antibody recognizing the latent form of
MMP2 (Chemicon International, Inc.). After washing with PBS-Tween
membranes were incubated for 1 h at room temperature with horseradish
peroxidase-conjugated anti–mouse IgG (Amersham Biosciences) diluted
1:5,000 in blocking solution. Immunoblots were developed using the ECL
detection system (Amersham Biosciences).
RT-PCR assays
Total RNA was isolated from preconfluent BC44 cell cultures using RNA-
plus reagent (Q-Biogene). For cDNA synthesis, RNA (1  g) was reverse
transcribed with oligo(dT) primer in a volume of 20  l, using the RT-PCR
kit from Takara Biomed. After heat inactivation of reverse transcriptase,
volume was adjusted to 100  l with water, and 2  l were used for each
PCR amplification with Dynazyme polymerase (Finnzymes). In order to
perform semiquantitative PCR, the number of cycles was optimized for
each set of primers (35 cycles for MMP2, 26 cycles for MT1-MMP, and 18
cycles for EF1 ). The following primers were used: 5 -AGACCATGCG-
GAAGCCAAGA-3  and 5 -CGTCGCTCCATACTTTTAAG-3  for MMP2
detection; 5 -GTGCCCTATGCCTACATCCG-3  and 5 -TTGGGTATC-
CGTCCATCACT-3  for MT1-MMP detection; 5 -CTGGAGCCAAGTGC-
TAATATGCC-3 ;  and 5 -GCCAGGCTTGAGAACACCAGTC-3  for EF1 
detection. The RT-PCR products were electrophoresed through a 1.5%
agarose gel containing ethidium bromide.
Immunocytochemical staining and flow cytometry
Cells were plated at low density on glass coverslips coated with FN or LN5
in 24-well tissue culture plates (TPP) and allowed to spread overnight in
EGF-free culture medium. For actin and vinculin staining, cells were fixed
with 4% formaldehyde in PBS for 10 min and permeabilised with 0.5%
Triton X-100 for 5 min at room temperature. Cells were incubated with pri-
mary antibodies for 1 h at 37 C and then with appropriate secondary anti-
bodies for 45 min at 37 C. Cells to be analyzed for the surface expression
of  1,  2,  5,  6,  v,  1, and  4 integrin subunits were harvested using
trypsin/EDTA, washed, incubated with primary antibody for 1 h at 4 C,
with secondary antibody for 45 min at 4 C, and fixed in 4% formaldehyde
overnight before analysis. Cells to be analyzed for expression of the  3 in-
tegrin subunit or EGFR were fixed in a mixture of 4% formaldehyde and
0.2% Triton X-100 (ICN Biochemicals) in PBS for 15 min at room tempera-
ture before incubation with antibodies. In control samples, isotype control
Igs were added to the incubation medium instead of the primary antibod-
ies. 5,000–10,000 cells per sample were analyzed in a FACScan analyzer
(Becton Dickinson) using Cell Quest software.
Antibodies used for immunofluorescence
The following primary antibodies were used: CKB1, mouse anti-cyto-
keratin peptide 14 (Sigma-Aldrich); rabbit polyclonal anti-cytokeratin 5
(BAbCo); Ks 18.04, mouse anti-cytokeratin 18 (PROGEN); rabbit poly-
clonal anti pan-keratin (DAKO); VIIF9, mouse anti-vinculin (Sigma-Aldrich);
hamster anti– 1-integrin subunit (Hm 1-1), rat anti– 1-integrin subunit
(9EG7), hamster anti– 1-integrin subunit (Ha31/8), hamster anti– 2-inte-
grin subunit (Hm 2), rat anti– 5-integrin subunit (5H10-27), rat anti– 6-
integrin subunit (GoH3), hamster anti– v-integrin subunit (H9.2B8), and
rat anti– 4-integrin subunit (346-11A; Pharmingen); rabbit polyclonal
anti– 3-integrin subunit, a gift from Dr. F. Watt (Imperial Cancer Research
Fund, London, UK); mouse anti-EGFR (Transduction Laboratories); and
rabbit polyclonal anti–laminin 5 (L132; Rousselle and Aumailley, 1994)
and rabbit polyclonal anti– -casein, a gift from Dr. D. Medina (Baylor Col-
lege of Medicine, Houston, TX). The following secondary antibodies were
used: Alexa 488-conjugated goat anti–rabbit IgG and Alexa 488-conju-
gated goat anti–mouse IgG (Molecular Probes); FITC- or Texas red–conju-
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goat anti–mouse IgG (Jackson ImmunoResearch Laboratories). Phalloidin-
Texas red (Molecular Probes) was used to reveal actin filaments.
Cell transplantation into cleared mammary fat pads, histology, 
and immunohistochemistry
Cleared mammary fat pads were prepared in 3-wk-old female Balb/c mice
by surgically removing the developing mammary epithelium of the fourth
inguinal glands as previously described (Young, 2000). Confluent BC44
cells grown in presence or absence of EGF were harvested with trypsin-
EDTA, rinsed with culture medium, and their concentration was adjusted to
10
8 cells/ml in PBS. Ten  l of EGF-treated or untreated BC44 cell suspen-
sions were injected into the right and left cleared fat pads of the same
mouse. 5 or 8 wk after transplantation, the mammary fat pads were re-
moved and prepared for analysis. For whole-mount staining, mammary fat
pads were flattened on microscope slides, fixed overnight in Carnoy’s solu-
tion (75% ethanol, 25% acetic acid), and stained with carmine alum as de-
scribed (Faraldo et al., 1998). Whole-mount preparations were photo-
graphed, rehydrated overnight in 50% ethanol, dehydrated again, cleared
in xylene, and embedded in paraffin. Sections of 5  m were deparaffinized,
stained with haematoxylin and eosin, or processed for immunofluorescence
labeling. To obtain frozen sections, freshly dissected mammary fat pads
were embedded in Tissue-Tek (Miles Diagnostic Division) and frozen in
isopentane cooled by liquid nitrogen. Before staining, 7- m cryosections
were fixed for 10 min in acetone at –20 C. Sections were incubated in 5%
FCS for 30 min, and then with primary antibodies overnight, and with ap-
propriate fluorescent secondary antibodies for 2 h at room temperature.
Nuclei were stained with 1  g/ml DAPI (Sigma-Aldrich). 
Zymography
Gelatin and plasminogen zymography was performed as described else-
where (Heussen and Dowdle, 1980). Semiconfluent cultures of BC44 cells
were incubated for 36 h in serum-free RPMI medium containing 5  g/ml
bovine insulin. The conditioned media were concentrated using Centricon
10 filter devices (Millipore). 2  g of total protein per analyzed sample
were loaded onto a nonreducing 10% SDS polyacrylamide gel containing
either copolymerized type-1 gelatin (1 mg/ml, Bio-Rad Laboratories), or a
mixture of casein (1 mg/ml; Sigma-Aldrich) and human plasminogen (10
 g/ml; Sigma-Aldrich). After electrophoresis, the gel was washed with
2.5% Triton X-100 to remove SDS and incubated for 48 h at 37 C in a sub-
strate buffer for the detection of gelatinolytic activity (50 mM Tris, 0.02%
Brij 35, 0.2 M NaCl, 5 mM CaCl2, pH 7.6), or for 24 h in a substrate buffer
for the detection of the caseinolytic activity (0.01 M glycine, pH 8.3). The
gel was stained with 0.1% Coomassie blue R250 and the proteolytic activ-
ity was visualized as colorless bands.
Reagents
Fibronectin, CI and CIV, LN1, and fatty acid–free BSA were purchased
from Sigma-Aldrich. Human LN5 was purified as previously described
(Rousselle and Aumailley, 1994), and it consists of a 1:1 mixture of pro-
cessed and unprocessed  2-containing molecules. Marimastat (BB2516),
provided by British Biotech Pharmaceuticals Ltd. (Oxford, UK), was used
at a concentration of 1  M, and purified human TIMP2 (Chemicon) at a
concentration of 3.5  g/ml.
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